Feedback

Feedback

Canada’s Drug Agency formally solicits feedback from a variety of groups  (health care professionals, patients, drug manufacturers, associations, and other interested parties) on projects and draft reports. We value all feedback and use it to shape and improve our work.

Calls for  feedback and respective deadlines are posted on the Open Calls for Feedback page. We also send notifications via our E-Alert e-mails and Twitter accounts @CDA_AMC .

We welcome comments at any time, but only those received during the consultation period will be considered for inclusion in our final documents. Guidance questions are listed below to help you organize your comments before they are submitted. Please note that draft documents are for consultation only and may change after feedback is received.

Because of operational limitations, we cannot reply individually to groups  explaining if and how feedback was used. However, all feedback is carefully considered by our project teams and advisory committees. We thank you in advance for your interest and participation.

If you have any questions about our process, please email [email protected].

Patient Input

Please note that there are separate processes for patient groups to provide input on drugs that are reviewed through our Drug Reimbursement Reviews program. Visit our Provide Input page for more information.
 

Feedback and Statement of Interests